ERT most commonly stands for enzyme replacement therapy, a treatment for rare inherited conditions where the body can’t produce a specific enzyme. It can also refer to estrogen replacement therapy, which treats menopause symptoms. Both are widely used in medicine, but they work in completely different ways and treat very different conditions.
Enzyme Replacement Therapy: The Basics
Enzyme replacement therapy treats inherited conditions where the body is missing or severely lacking a specific enzyme. Without that enzyme, certain substances build up inside cells and gradually damage organs and tissues. ERT works by delivering a lab-made version of the missing enzyme directly into the bloodstream through an IV infusion.
The replacement enzymes are manufactured using recombinant DNA technology, typically grown in human or animal cell lines. These lab-produced enzymes carry specific sugar molecules on their surface that act like address labels. Receptors on cell surfaces recognize those sugar tags, pull the enzyme inside the cell, and route it to the compartment where the buildup is happening. Once there, the replacement enzyme breaks down the accumulated material, doing the job the body’s own enzyme can’t.
Conditions Treated With ERT
Most conditions treated by enzyme replacement therapy fall into a category called lysosomal storage disorders. These are rare genetic diseases where waste products accumulate inside a specific cellular compartment (the lysosome) because the enzyme responsible for breaking them down is deficient. The major conditions with approved ERT treatments include:
- Gaucher disease (types 1 and 3): Fat-laden cells accumulate in the spleen, liver, and bone marrow. ERT for Gaucher type 1 was the first lysosomal storage disorder treated this way and remains the gold standard.
- Fabry disease: A buildup of a specific fat molecule damages the kidneys, heart, and nervous system.
- Pompe disease: Glycogen accumulates in muscle tissue, causing progressive weakness that can affect breathing and heart function.
- Mucopolysaccharidosis types 1, 2, and 6 (Hurler syndrome, Hunter syndrome, and Maroteaux-Lamy syndrome): Complex sugars build up throughout the body, affecting bones, joints, airways, and organs.
What Infusions Look Like
ERT is given as a recurring IV infusion, typically every one to two weeks, for the rest of a patient’s life. Session length varies by condition and dose. For Pompe disease, a standard infusion takes roughly 4 to 6 hours, not including prep time for setting up the IV, checking vital signs, and monitoring afterward. Some patients receiving higher doses may sit for even longer sessions.
Many patients eventually receive infusions at home through specialized home-care nursing services, which can reduce the disruption to daily life. Children on ERT grow up with these infusions as a regular part of their routine.
Side Effects and Immune Reactions
The most common side effects are mild infusion-related reactions, primarily chills, which occur in roughly 13% of patients and are associated with about 1% of total infusions. These reactions tend to decrease in both frequency and severity over time, sometimes on their own and sometimes with the help of premedication like antihistamines.
Because the replacement enzyme is a protein the body didn’t grow up making, some patients develop antibodies against it. In clinical trials for Fabry disease, about 3 out of 14 treated patients developed an antibody response, though their antibody levels gradually declined over time, suggesting the immune system learned to tolerate the treatment. Severe allergic reactions are rare, and dangerous antibody types (IgE) have not been detected in studies.
The Cost Problem
ERT is among the most expensive treatments in medicine. Because these diseases are rare and the enzymes are complex to manufacture, annual costs can be staggering. A cost-effectiveness analysis of ERT for Hunter syndrome estimated incremental treatment costs at approximately $9.5 million over a patient’s lifetime, with drug costs accounting for 99% of that figure. Annual treatment costs for individual lysosomal storage disorders commonly run into the hundreds of thousands of dollars per patient per year.
Insurance typically covers ERT, but access varies by country and health system. The extreme cost relative to the small patient populations makes these therapies a frequent topic in health economics debates.
Limitations of Enzyme Replacement Therapy
ERT is effective at reducing organ damage and improving quality of life, but it has real limitations. The infused enzymes circulate through the bloodstream and enter cells throughout the body, but they cannot cross the blood-brain barrier in meaningful amounts. This means ERT does little for the neurological symptoms that accompany several lysosomal storage disorders. Patients with brain involvement often need additional or alternative treatment strategies.
ERT also cannot reverse damage that has already occurred. It slows or halts disease progression and can improve organ function, but starting treatment early, ideally before significant damage accumulates, produces the best outcomes. This is one reason newborn screening programs for conditions like Pompe disease and Gaucher disease have expanded in recent years.
ERT as Estrogen Replacement Therapy
In a completely different medical context, ERT refers to estrogen replacement therapy, a form of hormone treatment for menopause. Roughly 1.5 million women between ages 45 and 55 experience menopausal symptoms including hot flashes, night sweats, mood disturbances, sleep problems, and vaginal dryness.
Estrogen replacement therapy is specifically the term used when estrogen is given alone, which is appropriate only for women who have had a hysterectomy. Women with an intact uterus need a combination of estrogen and progestin to prevent abnormal thickening of the uterine lining. Systemic estrogen (taken as a pill, patch, or injection) works best for hot flashes and night sweats, while local estrogen (vaginal creams or rings) targets dryness, itching, and pain during sex. Today, this treatment is more commonly referred to as hormone replacement therapy (HRT) or menopausal hormone therapy (MHT), so you’ll encounter “ERT” less often in this context than you used to.